Jacobs 1990b.

Clinical features and settings	Study period: n.r. Patient population: 16 patients with neuroblastoma, three with retinoblastoma and one with a malignant paraganglioma; with 30 ¹²³I‐ (n = 17) and ¹³¹I‐ (n = 13) MIBG scans. Consecutive series: n.r. Diagnostic work‐up: n.r. Time spans between symptoms and index test, between symptoms and reference standard and between index test and reference standard: n.r. Treatment between index test and reference standard: n.r.
Participants	Included patients: 12 children with a neuroblastoma and a ¹²³I‐MIBG scan at first diagnosis. Median age: n.r. for these 12 included patients; for all 16 patients: 17.5 months (range 1 to 72 months). Sex distribution: n.r. for these 12 included patients; for all 16 patients: 13 boys (81%), 3 girls (19%). INSS stage: n.r. for these 12 included patients;all 16 patients with neuroblastoma: 2 stage 1, 2 stage 2, 4 stage 3, 5 stage 4 and 3 stage 4S.
Study design	Cohort study. N.r. whether the study was retrospective or prospective.
Target condition and reference standard(s)	n.r.
Index and comparator tests	Index test: ¹²³I‐ and ¹³¹I‐MIBG scintigraphy. Radiofarmacon: ¹²³I‐ and ¹³¹I‐MIBG. Dose: around 2 mCi. Collimator: n.r. Matrix: n.r. Acquisition protocol: WB planar scans. Acquisition time: 24 hours after injection and 48 hours after injection in case of doubtful cases. Acquisition duration: n.r. Interfering medication: n.r. Thyroid prophylaxis: potassium perchlorate or lugol solution before and after ¹²³I‐MIBG injection. Positive test result: n.r. Number and expertise of observers: n.r. Interobserver concordance: n.r.
Follow‐up	n.r.
Notes	Results n.r. for ¹²³I‐MIBG scans separately from ¹³¹I‐MIBG scans. Contact information of the authors: not available.